Practical Pharmacist-Led Interventions to Improve Antimicrobial Stewardship in Ghana, Tanzania, Uganda and Zambia.
AMR
CwPAMS
antimicrobial resistance
antimicrobial stewardship
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
received:
08
05
2021
revised:
23
06
2021
accepted:
25
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
The World Health Organisation (WHO) and others have identified, as a priority, the need to improve antimicrobial stewardship (AMS) interventions as part of the effort to tackle antimicrobial resistance (AMR). An international health partnership model, the Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme, was established between selected countries in Africa (Ghana, Tanzania, Zambia and Uganda) and the UK to support AMS. This was funded by UK aid under the Fleming Fund and managed by the Commonwealth Pharmacists Association (CPA) and Tropical Health and Education Trust (THET). The primary aims were to develop local AMS teams and generate antimicrobial consumption surveillance data, quality improvement initiatives, infection prevention and control (IPC) and education/training to reduce AMR. Education and training were key components in achieving this, with pharmacists taking a lead role in developing and leading AMS interventions. Pharmacist-led interventions in Ghana improved access to national antimicrobial prescribing guidelines via the CwPAMS mobile app and improved compliance with policy from 18% to 70% initially for patients with pneumonia in one outpatient clinic. Capacity development on AMS and IPC were achieved in both Tanzania and Zambia, and a train-the-trainer model on the local production of alcohol hand rub in Uganda and Zambia. The model of pharmacy health partnerships has been identified as a model with great potential to be used in other low and middle income countries (LMICs) to support tackling AMR.
Identifiants
pubmed: 34287350
pii: pharmacy9030124
doi: 10.3390/pharmacy9030124
pmc: PMC8293468
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2015 Jul 10;10(7):e0132316
pubmed: 26161535
Infect Dis Ther. 2015 Sep;4(Suppl 1):51-64
pubmed: 26362295
Antimicrob Resist Infect Control. 2018 May 2;7:63
pubmed: 29744044
Lancet Infect Dis. 2016 Sep;16(9):1017-1025
pubmed: 27312577
Glob Heart. 2014 Sep;9(3):347-58
pubmed: 25667187
PLoS One. 2013 Nov 11;8(11):e78942
pubmed: 24244390
Am J Infect Control. 2015 Nov;43(11):e67-71
pubmed: 26315059
JAC Antimicrob Resist. 2020 Oct 22;2(4):dlaa092
pubmed: 34223045
JAC Antimicrob Resist. 2020 Feb 18;2(1):dlaa001
pubmed: 34222959
J Glob Antimicrob Resist. 2020 Sep;22:317-324
pubmed: 32247077
Antibiotics (Basel). 2020 Aug 29;9(9):
pubmed: 32872419
Global Health. 2018 Jul 17;14(1):69
pubmed: 30016970
BMJ. 2020 May 18;369:m1983
pubmed: 32423901
Euro Surveill. 2020 Nov;25(45):
pubmed: 33183403
Eur J Clin Pharmacol. 2006 Feb;62(2):135-42
pubmed: 16389536
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003543
pubmed: 23633313
J Antimicrob Chemother. 2011 Aug;66(8):1916-20
pubmed: 21642650
BMC Pediatr. 2011 Nov 25;11:109
pubmed: 22117602